/ Not yet recruitingNot Applicable An open label, one-arm, multiple dose study in patients with prostate cancer to demonstrate efficacy of a one month goserelin 3.6 mg implant in a two months treatment (2 application periods) and PK/PD analysis of Zoladex® 3.6 mg implant in additional 12 patients.
/ Unknown statusNot Applicable An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days - C_30060_P3_03
/ Unknown statusNot Applicable A double blind, two-period cross-over study to compare the analgesic efficacy and tolerability of a new modified release formulation of hydromorphone (Hydromorphone hydrochloride 8 mg, 16 mg, and 24 mg prolonged release capsules) applied twice daily after food intake (fed”) with the corresponding dosage strengths of the reference formulation Palladon® retard applied twice daily immediately after food intake (fed”) - C_21060_P3_04
100 Clinical Results associated with Acino Supply AG
0 Patents (Medical) associated with Acino Supply AG
100 Deals associated with Acino Supply AG
100 Translational Medicine associated with Acino Supply AG